# Comprehensive B-Vitamin Forms Evaluation
## Evidence-Based Analysis for NTRPX Systems Integration

**Document Version:** 1.0  
**Date:** January 24, 2026  
**Classification:** Internal R&D Evaluation  
**Scope:** All 8 essential B vitamins, all available supplemental forms

---

## Executive Summary

**RECOMMENDATION: FORM-SPECIFIC APPROVAL FOR NTRPX SYSTEMS**

This document provides the definitive evidence-based evaluation of all B-vitamin forms for NTRPX Systems integration. After comprehensive analysis of bioavailability data, clinical trials, mechanisms, and safety profiles, the following optimal forms are recommended:

| Vitamin | Optimal Form(s) | Confidence | Primary System |
|---------|-----------------|------------|----------------|
| **B1** | Benfotiamine + TTFD | HIGH | Sustain + Sprint |
| **B2** | Riboflavin-5'-Phosphate | MODERATE | All Systems |
| **B3** | Nicotinamide Riboside | HIGH | Recover |
| **B5** | D-Calcium Pantothenate | HIGH | All Systems |
| **B6** | Pyridoxal-5'-Phosphate | HIGH | All Systems |
| **B7** | D-Biotin | HIGH | All Systems |
| **B9** | L-5-MTHF (Quatrefolic) | HIGH | All Systems |
| **B12** | Methylcobalamin + Adenosylcobalamin | HIGH | All Systems |

**KEY PRINCIPLES APPLIED:**
- Evidence over theory
- Proven over promising
- Independent replication required
- No compromises on safety
- Bioavailable forms preferred over precursors
- Active coenzyme forms preferred where evidence supports

---

## Table of Contents

1. [Evaluation Standards](#1-evaluation-standards)
2. [B1: Thiamine](#2-b1-thiamine)
3. [B2: Riboflavin](#3-b2-riboflavin)
4. [B3: Niacin](#4-b3-niacin)
5. [B5: Pantothenic Acid](#5-b5-pantothenic-acid)
6. [B6: Pyridoxine](#6-b6-pyridoxine)
7. [B7: Biotin](#7-b7-biotin)
8. [B9: Folate](#8-b9-folate)
9. [B12: Cobalamin](#9-b12-cobalamin)
10. [Cross-Cutting Analysis](#10-cross-cutting-analysis)
11. [NTRPX Systems Integration](#11-ntrpx-systems-integration)
12. [Final Specifications](#12-final-specifications)
13. [References](#13-references)

---

## 1. Evaluation Standards

### NTRPX Evidence Hierarchy

```
┌─────────────────────────────────────────────────────────────────┐
│                    EVIDENCE QUALITY TIERS                       │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  TIER 1: PROVEN                                                 │
│  ├── Meta-analyses of RCTs                                      │
│  ├── Multiple independent RCTs (n≥30 each)                      │
│  └── Replicated findings across research groups                 │
│                                                                 │
│  TIER 2: PROBABLE                                               │
│  ├── Single large RCT (n≥100)                                   │
│  ├── Multiple smaller RCTs with consistent direction            │
│  └── Strong mechanistic + observational alignment               │
│                                                                 │
│  TIER 3: POSSIBLE                                               │
│  ├── Pilot RCTs (n<30)                                          │
│  ├── Observational studies only                                 │
│  └── Strong preclinical, limited human data                     │
│                                                                 │
│  TIER 4: THEORETICAL                                            │
│  ├── Preclinical only                                           │
│  ├── Mechanistic extrapolation                                  │
│  └── Traditional use without clinical validation                │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### Form Selection Criteria

| Criterion | Weight | Description |
|-----------|--------|-------------|
| **Bioavailability** | 30% | Absorption, tissue distribution, cellular uptake |
| **Clinical Evidence** | 25% | Human RCTs demonstrating superiority |
| **Safety Profile** | 20% | Adverse effects, toxicity thresholds, interactions |
| **Mechanism Validation** | 15% | Understanding of how form confers advantage |
| **Practical Factors** | 10% | Stability, cost, availability, formulation compatibility |

---

## 2. B1: Thiamine

### 2.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Coenzyme** | Thiamine diphosphate (ThDP/TPP) |
| **Key Enzymes** | Pyruvate dehydrogenase, α-ketoglutarate dehydrogenase, transketolase |
| **Primary Functions** | Glucose metabolism, ATP production, pentose phosphate pathway |
| **Deficiency Syndromes** | Beriberi (peripheral), Wernicke-Korsakoff (CNS) |
| **RDA** | 1.1-1.2 mg/day |

### 2.2 Available Forms

```
┌─────────────────────────────────────────────────────────────────┐
│                    THIAMINE FORM HIERARCHY                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  1. TTFD (Thiamine Tetrahydrofurfuryl Disulfide)               │
│     ├── Confirmed BBB penetration (PET imaging)                 │
│     ├── Superior CNS tissue distribution                        │
│     ├── Non-enzymatic membrane crossing                         │
│     ├── Unique non-coenzyme effects                             │
│     └── ★ RECOMMENDED FOR CNS/COGNITIVE                         │
│                                                                 │
│  2. BENFOTIAMINE (S-benzoylthiamine-O-monophosphate)           │
│     ├── 1,147% plasma bioavailability vs HCl                    │
│     ├── 196% erythrocyte ThDP vs HCl                            │
│     ├── Excellent peripheral tissue distribution                │
│     ├── BBB penetration uncertain/delayed                       │
│     └── ★ RECOMMENDED FOR PERIPHERAL/METABOLIC                  │
│                                                                 │
│  3. SULBUTIAMINE (O-isobutyryl Thiamine Disulfide)             │
│     ├── Crosses BBB                                             │
│     ├── Antiasthenic properties                                 │
│     ├── May cause mood issues without other B vitamins          │
│     └── ⚠️ CONDITIONAL - Specific applications only             │
│                                                                 │
│  4. THIAMINE HCl / MONONITRATE                                  │
│     ├── Poor bioavailability (saturable transport)              │
│     ├── Limited tissue penetration                              │
│     ├── Adequate for preventing deficiency                      │
│     └── ✗ NOT OPTIMAL - Use as baseline only                    │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 2.3 Form Comparison Table

| Form | Plasma Bioavailability | BBB Penetration | Tissue Distribution | Mechanism |
|------|----------------------|-----------------|---------------------|-----------|
| **Thiamine HCl** | Baseline (1x) | Poor | Limited | Active transport (THTR1/2) |
| **Benfotiamine** | 11.5x higher | Uncertain | Peripheral excellent | Enzymatic cleavage → thiamine |
| **TTFD** | ~5x higher | ✅ Confirmed | CNS + peripheral | Non-enzymatic reduction |
| **Sulbutiamine** | High | ✅ Confirmed | CNS emphasis | Non-enzymatic reduction |

### 2.4 Critical Distinction: Thioesters vs Disulfides

| Property | Thioesters (Benfotiamine) | Disulfides (TTFD, Sulbutiamine) |
|----------|---------------------------|--------------------------------|
| **Chemical class** | S-acyl derivative | Open-ring disulfide |
| **Membrane crossing** | Requires alkaline phosphatase | Non-enzymatic reduction |
| **BBB penetration** | Controversial/delayed | Confirmed |
| **Peak effect** | 1-2 hours | Rapid |
| **Primary target** | Peripheral tissues | CNS + peripheral |
| **Non-coenzyme effects** | AGE inhibition | Anti-inflammatory, antioxidant |

### 2.5 Clinical Evidence

#### Benfotiamine

| Study | Design | Population | Intervention | Outcome |
|-------|--------|------------|--------------|---------|
| Stracke et al. 1996 | RCT | Diabetic neuropathy | 320mg/day, 3 weeks | ✅ Significant symptom improvement |
| Haupt et al. 2005 | RCT | Diabetic neuropathy | 300mg/day, 6 weeks | ✅ Neuropathy score improved |
| Gibson et al. 2020 | Open-label | Mild AD (n=5) | 300mg/day, 18 months | ✅ Cognitive improvement (no placebo) |
| Bioavailability studies | Crossover | Healthy adults | Single dose | ✅ 1,147% vs thiamine HCl |

**Evidence Tier:** TIER 2 (Probable) for peripheral neuropathy; TIER 3 (Possible) for cognitive

#### TTFD

| Study | Design | Population | Intervention | Outcome |
|-------|--------|------------|--------------|---------|
| Mimori et al. 1996 | RCT | Mild cognitive impairment | 100mg/day, 12 weeks | ✅ Improved cognition vs control |
| Lonsdale (1973-2013) | Case series | Various neurological | Variable doses | ✅ Hundreds of patients, no toxicity |
| PET imaging studies | Mechanistic | Healthy | Single dose | ✅ Confirmed brain/spinal cord entry |

**Evidence Tier:** TIER 3 (Possible) - Strong mechanistic, limited RCT replication

### 2.6 Safety Profile

| Form | Adverse Effects | Toxicity Threshold | Drug Interactions |
|------|-----------------|-------------------|-------------------|
| **Benfotiamine** | Minimal; GI upset rare | None established; 2g/day tolerated | None significant |
| **TTFD** | Garlic odor possible; paradoxical reaction initially | None established | None significant |
| **Sulbutiamine** | Brain fog, mood changes reported | Caution at high doses | Unknown |
| **Thiamine HCl** | Extremely safe | None (water-soluble) | None significant |

**Paradoxical Reaction (TTFD):** Some individuals experience temporary worsening of symptoms when initiating TTFD. Mechanism: rapid mobilization of thiamine-dependent enzymes. Management: Start low (33mg), titrate up over 1-2 weeks.

### 2.7 NTRPX Recommendation: B1

```
┌─────────────────────────────────────────────────────────────────┐
│                 B1 THIAMINE - NTRPX VERDICT                     │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: DUAL-FORM APPROACH                             │
│                                                                 │
│  SUSTAIN/BOOST/RECOVER:                                         │
│  └── Benfotiamine 150-300mg                                     │
│      • Peripheral metabolic support                             │
│      • AGE inhibition                                           │
│      • Excellent safety profile                                 │
│                                                                 │
│  SPRINT (Cognitive Focus):                                      │
│  └── TTFD 50-100mg                                              │
│      • CNS penetration confirmed                                │
│      • Cognitive support                                        │
│      • Start at 50mg, may titrate                               │
│                                                                 │
│  BASELINE (All Formulas):                                       │
│  └── Thiamine HCl 10-25mg                                       │
│      • Insurance against deficiency                             │
│      • Negligible cost                                          │
│                                                                 │
│  AVOID: Sulbutiamine (mood concerns without full B-complex)     │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 3. B2: Riboflavin

### 3.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Coenzymes** | FMN (flavin mononucleotide), FAD (flavin adenine dinucleotide) |
| **Key Functions** | Electron transport, drug/steroid metabolism, B6/folate/niacin metabolism |
| **Enzymes Dependent** | ~70-80 flavoenzymes |
| **Deficiency Signs** | Angular cheilitis, glossitis, seborrheic dermatitis |
| **RDA** | 1.1-1.3 mg/day |

### 3.2 Available Forms

| Form | Structure | Notes |
|------|-----------|-------|
| **Riboflavin** | Free vitamin | Standard form; must be phosphorylated |
| **Riboflavin-5'-Phosphate (R5P/FMN)** | Phosphorylated | Active coenzyme form |
| **FAD** | Adenylated FMN | Full coenzyme; hydrolyzed before absorption |

### 3.3 Bioavailability Analysis

**Critical Finding:** All forms have similar bioavailability (~95%) because:
1. FAD and FMN are **hydrolyzed to free riboflavin** by intestinal phosphatases before absorption
2. Free riboflavin is then **re-phosphorylated** intracellularly by flavokinase
3. Absorption is **saturable** at ~27mg per dose regardless of form

| Form | Absorption | Conversion Required | Practical Difference |
|------|------------|--------------------|--------------------|
| **Riboflavin** | ~95% up to 27mg | Yes (flavokinase) | Standard |
| **R5P** | ~95% up to 27mg | Dephosphorylated, then rephosphorylated | Minimal for most people |
| **FAD** | ~95% up to 27mg | Fully hydrolyzed first | No advantage |

### 3.4 When R5P May Matter

R5P (riboflavin-5'-phosphate) may provide advantage in specific populations:

| Population | Rationale | Evidence Level |
|------------|-----------|----------------|
| **Impaired flavokinase activity** | Bypasses phosphorylation step | Theoretical |
| **MTHFR polymorphisms** | FMN required for MTHFR function | Indirect support |
| **Liver dysfunction** | Primary site of phosphorylation | Theoretical |
| **High-dose B6 users** | Flavokinase uses same enzyme family | Theoretical |

**Evidence Tier:** TIER 4 (Theoretical) for R5P superiority - No direct clinical trials comparing forms

### 3.5 Critical Metabolic Role

```
┌─────────────────────────────────────────────────────────────────┐
│              RIBOFLAVIN METABOLIC DEPENDENCIES                  │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RIBOFLAVIN → FMN → FAD                                         │
│       │                                                         │
│       ├──→ Required for B6 activation                           │
│       │    (Pyridoxine → PLP requires FMN-dependent oxidase)    │
│       │                                                         │
│       ├──→ Required for folate metabolism                       │
│       │    (MTHFR requires FAD as cofactor)                     │
│       │                                                         │
│       ├──→ Required for niacin synthesis                        │
│       │    (Tryptophan → NAD+ requires FAD)                     │
│       │                                                         │
│       └──→ Required for glutathione recycling                   │
│            (Glutathione reductase requires FAD)                 │
│                                                                 │
│  IMPLICATION: Riboflavin deficiency impairs B6, B9, B3 status   │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 3.6 Safety Profile

| Parameter | Value |
|-----------|-------|
| **UL** | None established |
| **Toxicity** | No known toxicity even at high doses |
| **Adverse effects** | Yellow-orange urine discoloration (harmless) |
| **Half-life** | ~1 hour (rapid turnover) |
| **Drug interactions** | Minimal; may reduce efficacy of some antibiotics |

### 3.7 NTRPX Recommendation: B2

```
┌─────────────────────────────────────────────────────────────────┐
│                 B2 RIBOFLAVIN - NTRPX VERDICT                   │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: RIBOFLAVIN-5'-PHOSPHATE (R5P)                  │
│                                                                 │
│  Rationale:                                                     │
│  • Provides active coenzyme form                                │
│  • Supports impaired phosphorylation (theoretical benefit)      │
│  • Better solubility for formulation                            │
│  • Marginal cost increase justified by precautionary principle  │
│  • No disadvantage vs free riboflavin                           │
│                                                                 │
│  ALL SYSTEMS: 10-25mg R5P                                       │
│                                                                 │
│  Migraine prevention: 400mg/day (either form acceptable)        │
│                                                                 │
│  Confidence: MODERATE                                           │
│  (No direct evidence of superiority, but no downside)           │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 4. B3: Niacin

### 4.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Coenzymes** | NAD+ (nicotinamide adenine dinucleotide), NADP+ |
| **Enzymatic Reactions** | >400 enzymes |
| **Key Functions** | Energy metabolism, DNA repair, sirtuin activation, PARP activity |
| **Age-Related Decline** | ~50% NAD+ reduction by age 60 |
| **Deficiency Syndrome** | Pellagra (dermatitis, diarrhea, dementia, death) |
| **RDA** | 14-16 mg NE/day |

### 4.2 Available Forms

```
┌─────────────────────────────────────────────────────────────────┐
│                      NIACIN FORM HIERARCHY                      │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  NAD+ PRECURSOR EFFICIENCY (Clinical 2023 Study, 1g doses):     │
│                                                                 │
│  1. NICOTINAMIDE             ████████████████████  MOST         │
│                                                                 │
│  2. NICOTINIC ACID (Niacin)  ████████████████                   │
│                                                                 │
│  3. NICOTINAMIDE RIBOSIDE    ██████████████                     │
│                                                                 │
│  4. NMN                      ████████████                       │
│                                                                 │
│  5. INOSITOL HEXANICOTINATE  ████              INEFFECTIVE      │
│     (Flush-free niacin)                                         │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 4.3 Form Comparison Table

| Form | NAD+ Boosting | Flush | Lipid Effects | Sirtuin Concern | Regulatory Status |
|------|---------------|-------|---------------|-----------------|-------------------|
| **Nicotinic Acid** | High | YES (vasodilation) | ✅ ↑HDL, ↓LDL/TG | None | GRAS |
| **Nicotinamide** | Highest | No | None | High doses may inhibit | GRAS |
| **NR (Niagen)** | Moderate-High | No | Minimal | None | GRAS |
| **NMN** | Moderate | No | Minimal | None | ⚠️ Not legal as supplement (FDA 2022) |
| **Inositol Hexanicotinate** | None/Minimal | No | None proven | N/A | GRAS |

### 4.4 Pathway Analysis

```
┌─────────────────────────────────────────────────────────────────┐
│                    NAD+ BIOSYNTHESIS PATHWAYS                   │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  NICOTINIC ACID (Preiss-Handler Pathway):                       │
│  Nicotinic acid → NaMN → NaAD → NAD+                            │
│  • 3 enzymatic steps                                            │
│  • Causes prostaglandin-mediated flush                          │
│                                                                 │
│  NICOTINAMIDE (Salvage Pathway):                                │
│  Nicotinamide → NMN → NAD+                                      │
│  • 2 enzymatic steps (most efficient)                           │
│  • Rate-limited by NAMPT enzyme                                 │
│  • High doses may inhibit sirtuins (product inhibition)         │
│                                                                 │
│  NICOTINAMIDE RIBOSIDE (NRK Pathway):                           │
│  NR → NMN → NAD+                                                │
│  • 2 enzymatic steps                                            │
│  • Bypasses NAMPT rate-limitation                               │
│  • Crosses cell membranes directly                              │
│  • No sirtuin inhibition concern                                │
│                                                                 │
│  NMN (Direct):                                                  │
│  NMN → NAD+                                                     │
│  • 1 step but requires dephosphorylation for cell entry         │
│  • Variable oral bioavailability                                │
│  • FDA ruled not legal as supplement (Nov 2022)                 │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 4.5 Clinical Evidence

#### Nicotinamide Riboside (NR)

| Study | Design | Population | Intervention | Outcome |
|-------|--------|------------|--------------|---------|
| Martens et al. 2018 | RCT | Healthy older adults (n=24) | 1g NR/day, 6 weeks | ✅ ↑NAD+ 60%, ↓BP trend |
| Dollerup et al. 2018 | RCT | Obese men (n=40) | 1g NR/day, 12 weeks | ✅ ↑NAD+, no metabolic changes |
| Elhassan et al. 2019 | RCT | Older adults (n=12) | 1g NR/day, 3 weeks | ✅ ↑NAD+ in muscle |
| Conze et al. 2019 | Safety | Healthy adults (n=140) | Up to 2g/day, 8 weeks | ✅ Well-tolerated |

**Evidence Tier:** TIER 2 (Probable) for NAD+ elevation; TIER 3 for functional outcomes

#### Nicotinamide

| Study | Design | Population | Intervention | Outcome |
|-------|--------|------------|--------------|---------|
| Multiple NAD+ studies | Comparative | Healthy adults | 1g single dose | ✅ Highest NAD+ boost |
| Diabetes prevention | Large RCTs | At-risk children | Various doses | ❌ Did not prevent T1D |

**Evidence Tier:** TIER 1 (Proven) for NAD+ elevation; functional benefits less clear

### 4.6 Safety Profile

| Form | Key Safety Concern | UL | Notes |
|------|-------------------|-----|-------|
| **Nicotinic Acid** | Hepatotoxicity at high doses; flush | 35mg (as niacin) | Sustained-release more hepatotoxic |
| **Nicotinamide** | Possible sirtuin inhibition; hepatotoxicity at very high doses | 35mg (as niacin) | Generally safer than nicotinic acid |
| **NR** | Well-tolerated | None established | Up to 2g/day in trials |
| **NMN** | Limited long-term data | N/A | Regulatory concerns |

### 4.7 NTRPX Recommendation: B3

```
┌─────────────────────────────────────────────────────────────────┐
│                   B3 NIACIN - NTRPX VERDICT                     │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  PRIMARY RECOMMENDATION: NICOTINAMIDE RIBOSIDE (NR)             │
│                                                                 │
│  Rationale:                                                     │
│  • Efficient NAD+ elevation without flush                       │
│  • No sirtuin inhibition concern                                │
│  • GRAS status, well-tolerated to 2g/day                        │
│  • Bypasses NAMPT rate-limitation                               │
│  • Clean regulatory status                                      │
│                                                                 │
│  RECOVER: 250-500mg NR (NAD+ support, cellular repair)          │
│  SUSTAIN: 100-250mg NR (maintenance)                            │
│                                                                 │
│  ALTERNATIVE: Nicotinamide 100-500mg                            │
│  • More cost-effective                                          │
│  • Higher NAD+ boost per mg                                     │
│  • Sirtuin concern only at very high doses (>1g)                │
│                                                                 │
│  AVOID:                                                         │
│  • Inositol hexanicotinate (ineffective for NAD+)               │
│  • NMN (regulatory issues)                                      │
│  • High-dose nicotinic acid (flush, hepatotoxicity)             │
│                                                                 │
│  Confidence: HIGH                                               │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 5. B5: Pantothenic Acid

### 5.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Coenzyme** | Coenzyme A (CoA) |
| **Key Functions** | Fatty acid synthesis/oxidation, acetylcholine synthesis, steroid hormones |
| **Ubiquity** | Name derives from Greek "pantos" (everywhere) - found in all foods |
| **Deficiency** | Extremely rare |
| **AI** | 5 mg/day |

### 5.2 Available Forms

| Form | Structure | Use Case |
|------|-----------|----------|
| **D-Calcium Pantothenate** | Calcium salt of D-pantothenic acid | Standard supplement form |
| **D-Pantothenic Acid** | Free acid | Less stable than calcium salt |
| **Pantethine** | Disulfide of pantetheine (CoA precursor) | Lipid modification |
| **Dexpanthenol** | Alcohol form (provitamin) | Topical/injectable |

### 5.3 Critical Distinction: Pantothenate vs Pantethine

**PANTETHINE ≠ PANTOTHENIC ACID clinically**

| Property | D-Calcium Pantothenate | Pantethine |
|----------|----------------------|------------|
| **Relationship to CoA** | 5 enzymatic steps away | 2 steps away (direct precursor) |
| **Lipid effects** | None demonstrated | ✅ Significant |
| **Dose for effect** | 5-10mg (RDA support) | 600-1200mg (therapeutic) |
| **Cost** | Low | High |
| **Primary use** | Nutritional | Therapeutic (dyslipidemia) |

### 5.4 Pantethine Clinical Evidence

| Study Type | Findings |
|------------|----------|
| Meta-analysis (2005) | 28 trials, n=646: ↓TG 32.9%, ↓TC 15.1%, ↓LDL 20.1%, ↑HDL 8.4% at 4 months |
| US RCT (2011) | n=32, 600mg/day: ↓TC 8.4%, ↓LDL 11.8%, maintained at 16 weeks |
| Mechanism studies | Inhibits HMG-CoA reductase, fatty acid synthesis; increases fatty acid oxidation |

**Evidence Tier:** TIER 2 (Probable) for pantethine lipid effects; TIER 4 (Theoretical) for pantothenate superiority over other forms

### 5.5 Safety Profile

| Parameter | Value |
|-----------|-------|
| **UL** | None established |
| **Toxicity** | No known toxicity |
| **Adverse effects** | Mild GI upset at very high doses (10g+) |
| **Drug interactions** | None significant |

### 5.6 NTRPX Recommendation: B5

```
┌─────────────────────────────────────────────────────────────────┐
│              B5 PANTOTHENIC ACID - NTRPX VERDICT                │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: D-CALCIUM PANTOTHENATE                         │
│                                                                 │
│  Rationale:                                                     │
│  • Standard form is sufficient for CoA synthesis                │
│  • No evidence other forms provide advantage for general use    │
│  • Cost-effective, stable, well-tolerated                       │
│  • Deficiency virtually impossible with any intake              │
│                                                                 │
│  ALL SYSTEMS: 10-50mg D-Calcium Pantothenate                    │
│                                                                 │
│  OPTIONAL ADD-ON (Lipid-focused formulas):                      │
│  └── Pantethine 300-600mg                                       │
│      • Only if targeting lipid modification                     │
│      • Significant cost increase                                │
│      • Not necessary for general B-vitamin support              │
│                                                                 │
│  Confidence: HIGH (for calcium pantothenate selection)          │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 6. B6: Pyridoxine

### 6.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Coenzyme** | Pyridoxal-5'-phosphate (PLP/P5P) |
| **Enzymatic Reactions** | >140 PLP-dependent enzymes (~4% of all classified activities) |
| **Key Functions** | Amino acid metabolism, neurotransmitter synthesis, hemoglobin, gene expression |
| **Half-life** | 25-33 days |
| **RDA** | 1.3-2.0 mg/day |

### 6.2 Available Forms

```
┌─────────────────────────────────────────────────────────────────┐
│                   B6 FORM HIERARCHY                             │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  1. PYRIDOXAL-5'-PHOSPHATE (P5P/PLP)                           │
│     ├── Active coenzyme form                                    │
│     ├── No conversion required                                  │
│     ├── MINIMAL NEUROTOXICITY                                   │
│     ├── Better retention                                        │
│     └── ★ NTRPX RECOMMENDED                                     │
│                                                                 │
│  2. PYRIDOXINE HCl                                              │
│     ├── Most common supplement form                             │
│     ├── Requires conversion to PLP                              │
│     ├── ⚠️ NEUROTOXICITY RISK AT HIGH DOSES                     │
│     ├── May competitively inhibit PLP                           │
│     └── ✗ NOT RECOMMENDED - Safety concern                      │
│                                                                 │
│  3. PYRIDOXAMINE                                                │
│     ├── Found in animal foods                                   │
│     ├── Intermediate form                                       │
│     └── Limited supplement availability                         │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 6.3 The Pyridoxine Paradox

**CRITICAL SAFETY FINDING:** High-dose pyridoxine supplementation can cause the very symptoms it should prevent.

| Mechanism | Explanation |
|-----------|-------------|
| **Competitive inhibition** | Inactive pyridoxine competes with active PLP for enzyme binding sites |
| **Neuronal toxicity** | Pyridoxine induces concentration-dependent cell death in neurons |
| **Sensory neuropathy** | >50 cases reported since 2014 of pyridoxine-induced peripheral neuropathy |
| **P5P safety** | Cell viability studies show minimal neurotoxicity with P5P |

```
┌─────────────────────────────────────────────────────────────────┐
│                  PYRIDOXINE PARADOX MECHANISM                   │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  HIGH-DOSE PYRIDOXINE                                           │
│        │                                                        │
│        ├──→ Overwhelms conversion enzymes                       │
│        │                                                        │
│        ├──→ Unphosphorylated pyridoxine accumulates             │
│        │                                                        │
│        ├──→ Competes with PLP for enzyme binding                │
│        │                                                        │
│        └──→ NET RESULT: Functional B6 deficiency                │
│                  └──→ Sensory neuropathy                        │
│                                                                 │
│  This does NOT occur with P5P supplementation                   │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 6.4 Conversion Pathway

| Step | Enzyme | Cofactor Required |
|------|--------|-------------------|
| Pyridoxine → Pyridoxine-5'-phosphate | Pyridoxal kinase | ATP |
| Pyridoxine-5'-phosphate → PLP | Pyridoxine-5'-phosphate oxidase | **FMN (B2)** |

**Implication:** B2 status affects B6 activation. Riboflavin deficiency impairs PLP production.

### 6.5 Clinical Evidence

| Study Type | Findings |
|------------|----------|
| Cell viability (2017) | Pyridoxine causes concentration-dependent neuronal death; P5P does not |
| Case series (2014-2024) | >50 cases pyridoxine-induced neuropathy at doses >50mg/day chronic |
| Bioavailability | P5P: Higher retention, more stable plasma levels |
| MTHFR populations | P5P may be preferred (no conversion bottleneck) |

**Evidence Tier:** TIER 2 (Probable) for P5P safety advantage; TIER 3 for efficacy superiority

### 6.6 Safety Profile

| Form | Neurotoxicity Risk | UL | Recommendation |
|------|-------------------|-----|----------------|
| **Pyridoxine HCl** | Significant at >50mg/day chronic | 100mg/day | Avoid high doses |
| **P5P** | Minimal | Not established separately | Preferred |

### 6.7 Drug Interactions

| Drug | Interaction | Clinical Action |
|------|-------------|-----------------|
| Levodopa | B6 increases peripheral conversion (reduces efficacy) | Use only with carbidopa |
| Phenytoin, phenobarbital | Increased B6 catabolism | May need supplementation |
| Cycloserine | Increased urinary B6 excretion | Supplement recommended |
| Isoniazid | B6 antagonist | Supplement required |

### 6.8 NTRPX Recommendation: B6

```
┌─────────────────────────────────────────────────────────────────┐
│                   B6 PYRIDOXINE - NTRPX VERDICT                 │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: PYRIDOXAL-5'-PHOSPHATE (P5P) EXCLUSIVELY       │
│                                                                 │
│  Rationale:                                                     │
│  • Active coenzyme form - no conversion required                │
│  • CRITICAL: Avoids pyridoxine neurotoxicity risk               │
│  • Better retention and utilization                             │
│  • Supports those with impaired conversion                      │
│  • Aligns with "no compromises on safety" principle             │
│                                                                 │
│  ALL SYSTEMS: 10-25mg P5P                                       │
│                                                                 │
│  DO NOT USE: Pyridoxine HCl in any NTRPX formula                │
│                                                                 │
│  Confidence: HIGH                                               │
│                                                                 │
│  Note: Higher cost of P5P is justified by safety advantage      │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 7. B7: Biotin

### 7.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Form** | D-Biotin (only biologically active form) |
| **Key Enzymes** | 5 carboxylases (pyruvate, acetyl-CoA, propionyl-CoA, methylcrotonyl-CoA, acetyl-CoA carboxylase 1&2) |
| **Key Functions** | Fatty acid synthesis, gluconeogenesis, amino acid catabolism |
| **Deficiency** | Very rare; screened at birth (biotinidase deficiency) |
| **AI** | 30 mcg/day |

### 7.2 Available Forms

**ONLY ONE BIOLOGICALLY ACTIVE FORM EXISTS**

| Form | Activity | Notes |
|------|----------|-------|
| **D-Biotin** | ✅ Active | The only form to use |
| **L-Biotin** | ❌ Inactive | Enantiomer, no biological activity |
| **Biocytin** | Precursor | Protein-bound form in food; cleaved to D-biotin |
| **DL-Biotin (racemic)** | 50% active | Avoid; half is inactive L-form |

### 7.3 Bioavailability

| Factor | Value |
|--------|-------|
| **Food bioavailability** | 5% to ~100% depending on source |
| **Supplement absorption** | ~100% even at pharmacologic doses (20mg) |
| **Transport** | SMVT (sodium-dependent multivitamin transporter) |
| **Storage** | Primarily liver |

### 7.4 Hair/Nail Claims: Evidence Assessment

**STATUS: NOT SUPPORTED BY EVIDENCE**

| Study Type | Findings |
|------------|----------|
| Systematic reviews | Insufficient evidence for hair/nail benefits in non-deficient individuals |
| RCTs | Studies had design flaws: no baseline biotin measurement, varied diagnoses |
| Confounding | Conditions like alopecia can resolve spontaneously |

**NTRPX Position:** Do not market biotin for hair/nail health. Deficiency is extremely rare, and supplementation in non-deficient individuals shows no benefit.

### 7.5 Lab Test Interference

**CRITICAL CLINICAL CONSIDERATION**

High-dose biotin can interfere with immunoassays using streptavidin-biotin interaction:

| Affected Tests | Direction | Clinical Impact |
|----------------|-----------|-----------------|
| Thyroid (TSH, T3, T4) | False positives/negatives | Misdiagnosis |
| Troponin | False negative | Missed MI |
| PSA | False negative | Missed cancer |
| Vitamin D | Variable | Incorrect supplementation |
| Pregnancy tests | Variable | Incorrect result |

**Recommendation:** Discontinue high-dose biotin 48-72 hours before lab work

### 7.6 Safety Profile

| Parameter | Value |
|-----------|-------|
| **UL** | None established |
| **Toxicity** | No known toxicity |
| **Adverse effects** | None at any dose studied |
| **Drug interactions** | Anticonvulsants may deplete; raw egg whites bind biotin |

### 7.7 NTRPX Recommendation: B7

```
┌─────────────────────────────────────────────────────────────────┐
│                   B7 BIOTIN - NTRPX VERDICT                     │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: D-BIOTIN                                       │
│                                                                 │
│  Rationale:                                                     │
│  • Only one active form exists - no form selection needed       │
│  • Ensure product specifies D-biotin (not DL-racemic)           │
│  • Deficiency extremely rare; low doses sufficient              │
│                                                                 │
│  ALL SYSTEMS: 30-100 mcg D-Biotin                               │
│                                                                 │
│  AVOID:                                                         │
│  • High-dose biotin (>1000 mcg) - lab interference concern      │
│  • Hair/nail health claims - not evidence-supported             │
│  • DL-Biotin (racemic) - 50% inactive                           │
│                                                                 │
│  Confidence: HIGH                                               │
│                                                                 │
│  Note: Include lab test warning on any high-dose products       │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 8. B9: Folate

### 8.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Form** | 5-methyltetrahydrofolate (5-MTHF, L-methylfolate) |
| **Key Functions** | DNA synthesis/repair, methylation, homocysteine metabolism, RBC formation |
| **Critical Period** | Pre-conception through first trimester (neural tube development) |
| **Deficiency** | Megaloblastic anemia, neural tube defects, elevated homocysteine |
| **RDA** | 400 mcg DFE/day; 600 mcg pregnancy |

### 8.2 Available Forms

```
┌─────────────────────────────────────────────────────────────────┐
│                     FOLATE FORM HIERARCHY                       │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  1. L-5-METHYLTETRAHYDROFOLATE (L-5-MTHF)                      │
│     ├── Active circulating form                                 │
│     ├── Bypasses entire folate metabolism                       │
│     ├── Not affected by MTHFR polymorphisms                     │
│     ├── Forms: Metafolin®, Quatrefolic®                         │
│     └── ★ NTRPX RECOMMENDED                                     │
│                                                                 │
│  2. FOLINIC ACID (Leucovorin/5-formyl-THF)                     │
│     ├── Reduced form, bypasses MTHFR                            │
│     ├── Few additional steps to active form                     │
│     ├── Good for methylation-sensitive individuals              │
│     └── ✓ Acceptable alternative                                │
│                                                                 │
│  3. FOLIC ACID (Synthetic)                                      │
│     ├── Requires multi-step conversion via slow DHFR            │
│     ├── ~40% population has impaired MTHFR conversion           │
│     ├── UMFA accumulation concern                               │
│     ├── Still CDC/WHO recommended for pregnancy (RCT evidence)  │
│     └── ⚠️ NOT PREFERRED - Use 5-MTHF instead                   │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 8.3 MTHFR Polymorphism

**CRITICAL POPULATION CONSIDERATION**

| Genotype | Prevalence | MTHFR Activity | Folic Acid Conversion |
|----------|------------|----------------|----------------------|
| **CC (wild-type)** | ~45% | 100% | Normal |
| **CT (heterozygous)** | ~45% | ~65% | Reduced |
| **TT (homozygous)** | ~10% | ~30% | Severely impaired |

**~40% of global population has reduced ability to convert folic acid to active 5-MTHF**

### 8.4 Folic Acid Concerns

| Concern | Explanation |
|---------|-------------|
| **UMFA accumulation** | Unmetabolized folic acid detectable in plasma at doses >200 mcg |
| **Receptor competition** | UMFA may compete with 5-MTHF for folate receptors |
| **DHFR saturation** | Enzyme is slow and easily overwhelmed |
| **Cord blood UMFA** | Detected in infants; long-term effects unknown |

### 8.5 5-MTHF Forms Comparison

| Branded Form | Salt | Bioavailability | Notes |
|--------------|------|-----------------|-------|
| **Quatrefolic®** | Glucosamine salt | Highest | Most soluble, stable |
| **Metafolin®** | Calcium salt | High | Well-established |
| **Generic L-5-MTHF** | Various | Variable | Ensure (6S) isomer specified |

**Important:** Only L- and (6S)- forms are biologically active. D- and (6R)- forms are not.

### 8.6 Clinical Evidence

| Study Type | Findings |
|------------|----------|
| MTHFR TT homocysteine | 5-MTHF: Sustained reduction 6 months post-treatment; folic acid: effect waned |
| Depression adjunct | 15mg L-methylfolate + SSRI: Significant improvement vs SSRI alone |
| Bioavailability | Quatrefolic: Higher Cmax and AUC than folic acid |
| Neural tube defects | **Folic acid only** has RCT evidence for NTD prevention (no 5-MTHF RCTs) |

**Evidence Tier:** TIER 1 (Proven) for folate necessity; TIER 2 (Probable) for 5-MTHF superiority in MTHFR populations

### 8.7 Safety Profile

| Form | Safety Concerns |
|------|-----------------|
| **5-MTHF** | Generally well-tolerated; may cause overmethylation symptoms in sensitive individuals |
| **Folic Acid** | UMFA accumulation; may mask B12 deficiency |
| **Folinic Acid** | Well-tolerated; may be better for methylation-sensitive |

### 8.8 NTRPX Recommendation: B9

```
┌─────────────────────────────────────────────────────────────────┐
│                   B9 FOLATE - NTRPX VERDICT                     │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: L-5-METHYLTETRAHYDROFOLATE (Quatrefolic®)      │
│                                                                 │
│  Rationale:                                                     │
│  • Active form - bypasses entire metabolic pathway              │
│  • Benefits ~40% of population with MTHFR variants              │
│  • No UMFA accumulation                                         │
│  • Superior bioavailability                                     │
│  • No B12 masking concern                                       │
│                                                                 │
│  ALL SYSTEMS: 400-800 mcg L-5-MTHF (as Quatrefolic®)            │
│                                                                 │
│  Specify: (6S)-5-methyltetrahydrofolate glucosamine salt        │
│                                                                 │
│  DO NOT USE: Folic acid in NTRPX formulas                       │
│                                                                 │
│  PREGNANCY NOTE:                                                │
│  CDC/WHO still recommend folic acid (only form with NTD RCT     │
│  evidence). For pregnancy-specific products, consider regulatory│
│  guidance, but 5-MTHF is mechanistically superior.              │
│                                                                 │
│  Confidence: HIGH                                               │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 9. B12: Cobalamin

### 9.1 Compound Overview

| Property | Value |
|----------|-------|
| **Active Coenzymes** | Methylcobalamin, Adenosylcobalamin |
| **Key Enzymes** | Methionine synthase (methylB12), L-methylmalonyl-CoA mutase (adenosylB12) |
| **Key Functions** | DNA synthesis, methylation, nerve function, RBC formation |
| **Deficiency** | Megaloblastic anemia, neurological damage (potentially irreversible) |
| **RDA** | 2.4 mcg/day |

### 9.2 Available Forms

```
┌─────────────────────────────────────────────────────────────────┐
│                   B12 FORM HIERARCHY                            │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  ACTIVE COENZYME FORMS:                                         │
│                                                                 │
│  1. METHYLCOBALAMIN                                             │
│     ├── Coenzyme for methionine synthase                        │
│     ├── Primary form in blood, liver, brain                     │
│     ├── Methyl donor for homocysteine → methionine              │
│     ├── Higher retention than cyanocobalamin                    │
│     └── ★ NTRPX RECOMMENDED (with adenosyl)                     │
│                                                                 │
│  2. ADENOSYLCOBALAMIN                                           │
│     ├── Coenzyme for methylmalonyl-CoA mutase                   │
│     ├── Primary form in mitochondria                            │
│     ├── Required for energy production, odd-chain FA metabolism │
│     ├── Less common as standalone supplement                    │
│     └── ★ NTRPX RECOMMENDED (with methyl)                       │
│                                                                 │
│  PRECURSOR FORMS:                                               │
│                                                                 │
│  3. HYDROXOCOBALAMIN                                            │
│     ├── Natural bacterial form                                  │
│     ├── Longest retention (binds serum proteins well)           │
│     ├── Converts to methyl or adenosyl in body                  │
│     ├── Preferred for injection/severe deficiency               │
│     └── ✓ Acceptable alternative                                │
│                                                                 │
│  4. CYANOCOBALAMIN                                              │
│     ├── Synthetic, most stable, cheapest                        │
│     ├── Contains cyanide molecule (trace, safe)                 │
│     ├── Requires conversion to active forms                     │
│     ├── Lower retention, greater urinary losses                 │
│     └── ⚠️ NOT OPTIMAL - Active forms preferred                 │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 9.3 Form Comparison Table

| Form | Coenzyme? | Retention | Conversion | Best Use |
|------|-----------|-----------|------------|----------|
| **Methylcobalamin** | ✅ Yes | Higher | None needed | Methylation, neuro |
| **Adenosylcobalamin** | ✅ Yes | Higher | None needed | Energy, mitochondria |
| **Hydroxocobalamin** | ❌ No | Highest | 1-2 steps | Injection, severe deficiency |
| **Cyanocobalamin** | ❌ No | Lower | 2+ steps | Budget formulas only |

### 9.4 Why Both Active Forms?

Methylcobalamin and adenosylcobalamin serve **different biochemical functions**:

```
┌─────────────────────────────────────────────────────────────────┐
│              B12 COENZYME FUNCTIONS                             │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  METHYLCOBALAMIN                                                │
│  └── Methionine Synthase                                        │
│       └── Homocysteine + 5-MTHF → Methionine + THF              │
│            ├── Methylation reactions (SAMe production)          │
│            ├── Regenerates THF for DNA synthesis                │
│            └── Location: Cytoplasm                              │
│                                                                 │
│  ADENOSYLCOBALAMIN                                              │
│  └── Methylmalonyl-CoA Mutase                                   │
│       └── L-methylmalonyl-CoA → Succinyl-CoA                    │
│            ├── Odd-chain fatty acid metabolism                  │
│            ├── Propionate metabolism                            │
│            ├── Energy production (TCA cycle entry)              │
│            └── Location: Mitochondria                           │
│                                                                 │
│  USING ONLY ONE FORM = INCOMPLETE B12 SUPPORT                   │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 9.5 Clinical Evidence

| Comparison | Findings |
|------------|----------|
| Methyl vs Cyano absorption | Similar initial absorption |
| Methyl vs Cyano retention | Methylcobalamin: Higher tissue retention, lower urinary losses |
| Liver storage | Cyanocobalamin: Lower hepatic accumulation |
| Neurological outcomes | Both effective; some preference for methylcobalamin in neuropathy |

**Evidence Tier:** TIER 2 (Probable) for active form advantage; direct comparison RCTs limited

### 9.6 Absorption Considerations

B12 absorption is complex and can be impaired:

| Factor | Impact |
|--------|--------|
| **Intrinsic factor** | Required for ileal absorption; absent in pernicious anemia |
| **Gastric acid** | Required to release B12 from food protein |
| **Age** | Absorption decreases with age (atrophic gastritis) |
| **Metformin** | Reduces B12 absorption |
| **PPIs, H2 blockers** | Reduce gastric acid, impair B12 release |
| **Passive diffusion** | ~1% absorbed without IF (relevant for high-dose supplements) |

### 9.7 Safety Profile

| Parameter | Value |
|-----------|-------|
| **UL** | None established |
| **Toxicity** | No known toxicity at any dose |
| **Adverse effects** | Rare: acne, rosacea flare (high-dose methylcobalamin) |
| **Drug interactions** | See absorption factors above |

### 9.8 NTRPX Recommendation: B12

```
┌─────────────────────────────────────────────────────────────────┐
│                  B12 COBALAMIN - NTRPX VERDICT                  │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  RECOMMENDATION: METHYLCOBALAMIN + ADENOSYLCOBALAMIN            │
│                                                                 │
│  Rationale:                                                     │
│  • Both active coenzyme forms - no conversion required          │
│  • Each serves distinct biochemical functions                   │
│  • Higher retention than cyanocobalamin                         │
│  • Supports methylation AND energy production                   │
│  • No cyanide molecule (relevant for smokers, detox)            │
│                                                                 │
│  ALL SYSTEMS:                                                   │
│  • Methylcobalamin: 500-1000 mcg                                │
│  • Adenosylcobalamin: 250-500 mcg                               │
│                                                                 │
│  Alternative (budget): Hydroxocobalamin 1000 mcg                │
│  (Converts to both active forms; better retention than cyano)   │
│                                                                 │
│  DO NOT USE: Cyanocobalamin as primary B12 source               │
│                                                                 │
│  Confidence: HIGH                                               │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

---

## 10. Cross-Cutting Analysis

### 10.1 Methylation Pathway Integration

The methylation cycle requires coordinated function of B2, B6, B9, and B12:

```
┌─────────────────────────────────────────────────────────────────┐
│                  METHYLATION CYCLE INTEGRATION                  │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│                     DIETARY FOLATE                              │
│                          │                                      │
│                          ▼                                      │
│                    Dihydrofolate                                │
│                          │ (DHFR)                               │
│                          ▼                                      │
│                 Tetrahydrofolate (THF)                          │
│                          │                                      │
│                          ▼                                      │
│               5,10-Methylenetetrahydrofolate                    │
│                          │                                      │
│                          │ MTHFR (requires FAD from B2)         │
│                          ▼                                      │
│     ┌──────────► 5-MTHF ◄──────────┐                           │
│     │                │              │                           │
│     │                │ Methionine   │                           │
│     │                │ Synthase     │                           │
│     │                │ (requires    │                           │
│     │                │ MethylB12)   │                           │
│     │                ▼              │                           │
│     │         METHIONINE            │                           │
│     │                │              │                           │
│     │                ▼              │                           │
│     │              SAMe             │                           │
│     │     (universal methyl donor)  │                           │
│     │                │              │                           │
│     │                ▼              │                           │
│     │         HOMOCYSTEINE ─────────┘                           │
│     │                │                                          │
│     │                │ CBS (requires P5P from B6)               │
│     │                ▼                                          │
│     │           Cystathionine                                   │
│     │                │                                          │
│     │                ▼                                          │
│     │            Cysteine → Glutathione                         │
│     │                                                           │
│     └───────────── THF ◄────────────                            │
│                                                                 │
│  NTRPX IMPLICATION: All four vitamins must be in active forms   │
│  for optimal methylation support                                │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
```

### 10.2 Energy Metabolism Integration

B1, B2, B3, and B5 coordinate in energy production:

| Vitamin | Coenzyme | Role in Energy Metabolism |
|---------|----------|---------------------------|
| **B1** | ThDP | Pyruvate dehydrogenase, α-ketoglutarate dehydrogenase |
| **B2** | FAD/FMN | Electron transport chain, fatty acid oxidation |
| **B3** | NAD+/NADP+ | >400 redox reactions, TCA cycle, glycolysis |
| **B5** | CoA | Acetyl-CoA formation, fatty acid synthesis/oxidation |

### 10.3 B Vitamin Synergies

| Interaction | Mechanism | NTRPX Implication |
|-------------|-----------|-------------------|
| **B2 → B6** | FMN required for pyridoxine oxidase | Ensure adequate B2 with P5P |
| **B2 → B9** | FAD required for MTHFR | Ensure adequate B2 with 5-MTHF |
| **B2 → B3** | FAD required for tryptophan→NAD+ | B2 supports niacin status |
| **B9 ↔ B12** | Methylation cycle partners | Always supplement together |
| **B6 → B9/B12** | CBS enzyme requires P5P | B6 affects homocysteine clearance |

### 10.4 Dosing Ratios

Based on RDA ratios and synergistic requirements:

| Vitamin | RDA | NTRPX Suggested | Ratio to B2 |
|---------|-----|-----------------|-------------|
| **B1** | 1.2 mg | 25-100 mg (benfotiamine) | 2-8x |
| **B2** | 1.3 mg | 10-25 mg (R5P) | 1x (baseline) |
| **B3** | 16 mg | 100-500 mg (NR or NAM) | 8-40x |
| **B5** | 5 mg | 25-100 mg | 2-8x |
| **B6** | 1.7 mg | 10-25 mg (P5P) | 1-2x |
| **B7** | 30 mcg | 100-300 mcg | - |
| **B9** | 400 mcg | 400-800 mcg (5-MTHF) | - |
| **B12** | 2.4 mcg | 500-1000 mcg (methyl+adenosyl) | - |

---

## 11. NTRPX Systems Integration

### 11.1 All Systems Go - Sustain

| Vitamin | Form | Dose | Rationale |
|---------|------|------|-----------|
| **B1** | Benfotiamine | 150-300 mg | Peripheral metabolic support, AGE inhibition |
| **B2** | R5P | 15-25 mg | Coenzyme form, supports B6/B9 function |
| **B3** | NR or Nicotinamide | 250-500 mg | NAD+ maintenance |
| **B5** | D-Calcium Pantothenate | 50-100 mg | CoA synthesis |
| **B6** | P5P | 15-25 mg | Active form, avoids neurotoxicity |
| **B7** | D-Biotin | 100-300 mcg | Carboxylase support |
| **B9** | L-5-MTHF (Quatrefolic) | 400-800 mcg | Methylation, no MTHFR concern |
| **B12** | Methyl + Adenosyl | 500 + 250 mcg | Both coenzyme forms |

### 11.2 All Systems Go - Boost

| Vitamin | Form | Dose | Rationale |
|---------|------|------|-----------|
| **B1** | Benfotiamine | 150 mg | Energy metabolism |
| **B2** | R5P | 10-15 mg | Electron transport |
| **B3** | Nicotinamide | 100-250 mg | NAD+ for acute energy |
| **B5** | D-Calcium Pantothenate | 25-50 mg | CoA availability |
| **B6** | P5P | 10-15 mg | Neurotransmitter synthesis |
| **B7** | D-Biotin | 100 mcg | Standard support |
| **B9** | L-5-MTHF | 400 mcg | Methylation |
| **B12** | Methylcobalamin | 500 mcg | Cognitive support |

### 11.3 All Systems Go - Recover

| Vitamin | Form | Dose | Rationale |
|---------|------|------|-----------|
| **B1** | Benfotiamine | 150-300 mg | Tissue repair, antioxidant |
| **B2** | R5P | 15-25 mg | Glutathione recycling |
| **B3** | NR | 250-500 mg | NAD+ for cellular repair |
| **B5** | D-Calcium Pantothenate | 50-100 mg | Wound healing support |
| **B6** | P5P | 15-25 mg | Protein metabolism |
| **B7** | D-Biotin | 100-300 mcg | Standard support |
| **B9** | L-5-MTHF | 600-800 mcg | Cell turnover, DNA repair |
| **B12** | Methyl + Adenosyl | 750 + 500 mcg | Elevated for recovery |

### 11.4 Sprint (Cognitive Focus)

| Vitamin | Form | Dose | Rationale |
|---------|------|------|-----------|
| **B1** | TTFD | 50-100 mg | Confirmed BBB penetration |
| **B2** | R5P | 10-15 mg | Neural metabolism |
| **B3** | Nicotinamide | 100-250 mg | Brain NAD+ |
| **B5** | D-Calcium Pantothenate | 25-50 mg | Acetylcholine precursor |
| **B6** | P5P | 10-25 mg | Neurotransmitter synthesis |
| **B7** | D-Biotin | 100 mcg | Standard support |
| **B9** | L-5-MTHF | 400 mcg | Neural methylation |
| **B12** | Methylcobalamin | 1000 mcg | Cognitive, methylation |

---

## 12. Final Specifications

### 12.1 NTRPX B-Vitamin Specification Summary

| Vitamin | Approved Form(s) | NOT Approved |
|---------|------------------|--------------|
| **B1** | Benfotiamine, TTFD, Thiamine HCl (baseline) | Sulbutiamine |
| **B2** | Riboflavin-5'-Phosphate (R5P) | - |
| **B3** | Nicotinamide Riboside, Nicotinamide | Inositol hexanicotinate, NMN |
| **B5** | D-Calcium Pantothenate, Pantethine (lipid only) | - |
| **B6** | Pyridoxal-5'-Phosphate (P5P) | Pyridoxine HCl |
| **B7** | D-Biotin | DL-Biotin (racemic) |
| **B9** | L-5-MTHF (Quatrefolic preferred) | Folic acid |
| **B12** | Methylcobalamin + Adenosylcobalamin | Cyanocobalamin |

### 12.2 Quality Standards

| Parameter | Specification |
|-----------|---------------|
| **Identity** | HPLC confirmation of stated forms |
| **Purity** | ≥98% for all vitamins |
| **Heavy metals** | USP \<232>/\<233> limits |
| **Microbial** | USP \<2021> standards |
| **Stability** | 24-month shelf life at room temperature |
| **Third-party testing** | Required for all batches |

### 12.3 Supplier Recommendations

| Vitamin | Preferred Supplier/Brand |
|---------|-------------------------|
| **Benfotiamine** | Multiple generic sources acceptable |
| **TTFD** | Ecological Formulas (Allithiamine), Thiamax |
| **R5P** | DSM, BASF |
| **NR** | ChromaDex (Niagen®) |
| **P5P** | DSM, BASF |
| **L-5-MTHF** | Gnosis (Quatrefolic®), Merck (Metafolin®) |
| **Methylcobalamin** | Multiple sources; ensure light-protected |
| **Adenosylcobalamin** | Specialty suppliers; verify stability |

---

## 13. References

### Primary Sources by Vitamin

**Thiamine (B1)**
1. Lonsdale D. A Review of the Biochemistry, Metabolism and Clinical Benefits of Thiamin(e) and Its Derivatives. Evidence-Based Complementary and Alternative Medicine. 2006;3(1):49-59.
2. Raj V, et al. Therapeutic potential of benfotiamine and its molecular targets. European Review for Medical and Pharmacological Sciences. 2018;22:3261-3273.
3. Pan X, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and β-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. 2010;133(5):1342-1351.
4. Gibson GE, et al. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J Alzheimers Dis. 2020;78(3):989-1010.

**Riboflavin (B2)**
5. Powers HJ. Riboflavin (vitamin B-2) and health. Am J Clin Nutr. 2003;77(6):1352-1360.
6. Schoenen J, et al. Effectiveness of high-dose riboflavin in migraine prophylaxis. Neurology. 1998;50(2):466-470.

**Niacin (B3)**
7. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9:1286.
8. Elhassan YS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019;28(7):1717-1728.

**Pantothenic Acid (B5)**
9. Rumberger JA, et al. Pantethine, a derivative of vitamin B5 used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects. Nutr Res. 2011;31(8):608-615.

**Pyridoxine (B6)**
10. Vrolijk MF, et al. The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicology in Vitro. 2017;44:206-212.
11. Hadtstein F, Vrolijk M. Vitamin B-6-Induced Neuropathy: Exploring the Mechanisms of Pyridoxine Toxicity. Advances in Nutrition. 2021;12(5):1911-1929.

**Biotin (B7)**
12. Patel DP, et al. A Review of the Use of Biotin for Hair Loss. Skin Appendage Disorders. 2017;3(3):166-169.
13. Li D, et al. Biotin interference in clinical immunoassays. J Appl Lab Med. 2020;5(3):452-461.

**Folate (B9)**
14. Scaglione F, Panzavolta G. Folate, folic acid and 5-methyltetrahydrofolate are not the same thing. Xenobiotica. 2014;44(5):480-488.
15. Prinz-Langenohl R, et al. [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C→T polymorphism of methylenetetrahydrofolate reductase. Br J Pharmacol. 2009;158(8):2014-2021.

**Cobalamin (B12)**
16. Paul C, Brady DM. Comparative Bioavailability and Utilization of Particular Forms of B12 Supplements With Potential to Mitigate B12-related Genetic Polymorphisms. Integr Med (Encinitas). 2017;16(1):42-49.
17. Obeid R, et al. Cobalamin coenzyme forms are not likely to be superior to cyano- and hydroxyl-cobalamin in prevention or treatment of cobalamin deficiency. Mol Nutr Food Res. 2015;59(7):1364-1372.

---

## Document Control

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 1.0 | 2026-01-24 | NTRPX R&D | Initial comprehensive evaluation |

---

*This document represents NTRPX's internal evaluation based on available clinical evidence as of the document date. Form selections are based on the principles of evidence over theory, proven over promising, and no compromises on safety. All recommendations are subject to revision as new evidence emerges.*